PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including three taken from inception at PureTech to FDA approval.
Neuropsychiatric conditions
31.2% Equity and 3-5% tiered royalties on Glyph product net sales; modest regulatory and commercial milestone payments
Phase 2
See Our Program
Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
35.4% Equity
Phase 3
See Our Program
Cobenfy™ (formerly known as KarXT) Now FDA Approved for the Treatment of Schizophrenia in Adults
PureTech retains rights to certain regulatory and commercial milestone payments related to Cobenfy™ in addition to 2% royalties on annual Cobenfy sales above $2B1
FDA Approved
See Our Program
Myeloid malignancies, such as relapsed/refractory (R/R) high-risk (HR) myelodysplastic syndrome and R/R acute myeloid leukemia (AML)
100% Equity
Phase 1/2
See Our Program

1As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna/BMS, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

Note: Ownership in Gallop Oncology was calculated as of December 31, 2025. PureTech controls Gallop Oncology. Ownership interest in Celea Therapeutics was calculated on a fully diluted basis as of July 1, 2026. Relevant ownership in Seaport Therapeutics is as of June 5, 2026.

PureTech Level Cash, Cash Equivalents

$248.1M
PureTech Level Cash, Cash Equivalents as of March 31, 20261
1 PureTech level cash and cash equivalents as of March 31, 2026, is an unaudited figure and excludes cash and cash equivalents at non-wholly owned subsidiary of $0.1m. PureTech level cash and cash equivalents is a non-IFRS measure.

Developing breakthrough medicines at PureTech